tcbiopharm.com (TCBP) Company Sales Volume
TC Biopharm (TCBP) aggregated sales demonstrate revenue dynamics where the 0.00 indicator expresses the state of the metric. High demand for unique cell therapy guarantees TC Biopharm (TCBP) pricing power. However, high production costs and potential security breaches create financial threats. The launch of new clinical trials for leukemia treatment will be a positive factor and serve as the primary growth driver.
Analytical breakdowns for TC BioPharm (TCBP)
- price and consensus price forecast:
- market capitalization details:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Equity Ratio TC Biopharm|TCBP - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital TC BioPharm (Holdings) Plc|TCBP - Company Aggregate Debts|Debt to Book Capitalization Ratio TC BioPharm (Holdings) Plc|TCBP - Company Long-Term Debts|Short-Term Debt Volume TC BioPharm|Immediate Liquidity tcbiopharm.com
- business earnings and investment ratios data:
TCBP - Company Net Income|Forward Earnings TC Biopharm|TCBP - P/E Multiple|Future Price to Earnings Multiple tcbiopharm.com|TCBP - PEG Multiple|EV/EBITDA Multiple TC BioPharm (Holdings) Plc|TCBP - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year TC BioPharm|TCBP - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months tcbiopharm.com|TCBP - Net earnings per share growth this year|Projected earnings per share increase next year TC Biopharm
- issuer revenue and sales details:
Summary company analysis:TC BioPharm Ltd
This indicator aggregates daily cash inflows from product sales, reflecting operational efficiency and liquidity through the lens of actual shipments. The current value of 0.00 confirms the ability of TC Biopharm (TCBP) to maintain commercial activity while implementing costly ESG standards in cancer immunotherapy, allowing investors to assess business resilience based on the company's gross sales volume.
Key competitors
Revenue and Sales Volume argenx BVBA|Company Revenue BioNTech SE (BNTX)|Abivax SA - Company Sales Volume|Revenue and Sales Volume ADMA (ADMA Biologics, Inc.)|Protagonist Therapeutics, Inc. (PTGX) - Company Total Revenue|IMVT: Company Sales|Kiniksa Corp - Company Total Sales|GRFS: Revenue and Sales Volume|Company Sales adaptivebiotech.com|Company Sales CLDX|AUPH: Company Sales Revenue|Revenue and Sales Volume BCRX|Company Revenue VERA (Vera Corp)|Revenue and Sales Volume DNTH (Dianthus Therapeutics)|Company Gross Revenue pharvaris.com (PHVS)|ABCL - Company Revenue|Company Total Revenue Tourmaline Bio Inc|Intrexon (PGEN) - Company Revenue|Company Annual Revenue PHAR (Pharming Corp)|NKTR (Nektar Therapeutics) - Revenue and Sales Volume|UPB: Company Sales Revenue|Revenue and Sales Volume ZBIO|Revenue and Sales Volume Immunome Inc (IMNM)|Company Revenue Gossamer Corp GOSS|Company Sales Revenue KALV|SEPN - Company Revenue|pieris.com (PVLA) - Company Sales|SVRA (Savara) - Company Sales|RIGL: Company Total Sales|ANAB (AnaptysBio Corp) - Revenue and Sales Volume|Company Sales Astria Corp (ATXS)|Revenue and Sales Volume ENGN|Company Revenue RAPT (rapt.com)|Company Revenue Aerovate Therapeutics JBIO|ACRS (Aclaris Therapeutics Inc.) - Company Annual Revenue|KYTX - Company Revenue|Company Annual Revenue TLSA|CABA: Revenue and Sales Volume|ventyxbio.com - Company Sales Revenue|THTX (Theratechnologies) - Revenue and Sales Volume|Revenue and Sales Volume Avalo Therapeutics, Inc.|Company Revenue Eledon (ELDN)|AGEN (Agenus, Inc) - Company Sales Revenue|Company Revenue Climb Bio Inc CLYM|ZURA - Company Sales|aTyr Pharma - Revenue and Sales Volume|ADAG - Revenue and Sales Volume|IMA (ikenaoncology.com) - Company Sales|Shattuck Labs - Company Sales Revenue|EQ (Equillium Inc) - Revenue and Sales Volume|Connect Pharma (CNTB) - Company Gross Revenue|Company Revenue Immunic, Inc. (IMUX)|Company Sales atarabio.com ATRA|Company Revenue InflaRx IFRX|XFOR - Company Sales|ACET: Company Sales|CELU - Revenue and Sales Volume|INmune Bio (INMB) - Company Revenue|Company Sales Volume BRNS|KZR (Kezar Life Sciences, Inc) - Revenue and Sales Volume|Company Total Revenue SAB Biotherapeutics Inc SABS|Company Sales AKTX (Akari Therapeutics)|Company Total Sales ENLV|Revenue and Sales Volume QTTB (Q32 Bio)|GOVX - Company Sales|EDSA: Company Sales|Company Sales Revenue IBIO (iBio Corporation)|CARM: Revenue and Sales Volume|XTLB (xtlbio.com) - Company Revenue|BOLT (Bolt Biotherapeutics Inc.) - Revenue and Sales Volume|HCW Biologics Inc (HCWB) - Company Gross Revenue|Company Revenue Aptevo Therapeutics (APVO)|AIM - Company Total Revenue|Company Revenue Aditxt, Inc. ADTX|GRI (gribio.com) - Company Annual Revenue|XORTX Therapeutics - Revenue and Sales Volume|Company Sales Revenue HIND (Vyome Holdings Inc.)|REVB: Revenue and Sales Volume|Indaptus Corp (INDP) - Revenue and Sales Volume|Company Revenue Scinai Immunotherapeutics|CALI: Company Sales Revenue|Company Revenue Affimed (AFMD)|Company Sales allakos.com ALLK|HOOKIPA Pharma - Company Sales|Company Total Sales IGMS (IGM Biosciences Inc.)|iTeos Therapeutics - Revenue and Sales Volume|oceanbiomedical.com (OCEA) - Company Sales|THRD: Revenue and Sales Volume
